Research

DGI BioTechnologies, Novo Nordisk Collaborate to Discover Anticancer Agents

Published in Cancer Weekly, January 29th, 2002

DGI BioTechnologies, Inc., has signed a two-year licensing and research agreement with Novo Nordisk A/S, for the research and discovery of IGF-related antagonists for the treatment of cancer.

Under terms of the agreement, DGI becomes an equal research partner for in vitro and in vivo testing. Novo Nordisk will obtain exclusive rights to IGF antagonists, while DGI will maintain rights to IGF agonists that are discovered as a result of the collaboration. Financial terms of the agreement were not disclosed.

IGF, or insulin-like growth factor, is a natural growth-promoting entity, the blockage of whose action has attracted attention as a potential...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2002-01-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry